Please refer to the eCQI resource center for more information on the QDM.įollow-Up Care for Children Prescribed ADHD Medication (ADD) This version of the eCQM uses QDM version 5.5. Numerator 2: Patients who had at least one visit with a practitioner with prescribing authority during the Initiation Phase, and at least two follow-up visits during the Continuation and Maintenance Phase.ĭenominator Exclusion 1: Exclude patients diagnosed with narcolepsy at any point in their history or during the measurement period.Įxclude patients who had an acute inpatient stay with a principal diagnosis of mental health or substance abuse during the 30 days after the IPSD.Įxclude patients who were actively on an ADHD medication in the 120 days prior to the Index Prescription Start Date.Įxclude patients who are in hospice care for any part of the measurement period.ĭenominator Exclusion 2: Exclude patients diagnosed with narcolepsy at any point in their history or during the measurement period.Įxclude patients who had an acute inpatient stay with a principal diagnosis of mental health or substance abuse during the 300 days after the IPSD. Numerator 1: Patients who had at least one visit with a practitioner with prescribing authority within 30 days after the IPSD. Initial Population 2: Children 6-12 years of age who were dispensed an ADHD medication during the Intake Period and who remained on the medication for at least 210 days out of the 300 days following the IPSD, and who had a visit during the measurement period.

Initial Population 1: Children 6-12 years of age who were dispensed an ADHD medication during the Intake Period and who had a visit during the measurement period. Percentage of children who remained on ADHD medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two additional follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended. Percentage of children who had one follow-up visit with a practitioner with prescribing authority during the 30-Day Initiation Phase.ī. Percentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care.

Add medication